Magnus Medical, the company that received FDA clearance for the SAINT-derived SNT (Stanford Neuromodulation Therapy) protocol in 2022, raised $90 million in Series C funding to scale commercial deployment. The round was led by major healthcare-focused venture investors and brings total funding to approximately $215 million.
Magnus's device differs from standard TMS systems in that it integrates resting-state functional MRI for personalized targeting and supports the high-throughput five-day SAINT-style protocol. The device is currently deployed at roughly 50 U.S. clinics, with expansion to an additional 100 sites planned over the next 18 months.
Insurance coverage for accelerated SAINT-style protocols has been a persistent barrier; the recent Aetna policy change removing step-therapy requirements is expected to substantially improve coverage prospects across the broader payer mix.
Industry analysts note that the funding round signals significant investor confidence in the accelerated TMS market segment, despite the hardware and infrastructure costs of fMRI-guided protocols.
Source
Reporting based on coverage from MedTech Dive. This article is editorial summary intended for general information; it is not medical advice.